VANCOUVER, B.C.–BioHarvest Sciences Inc. (CSE: BHSC) announces that online sales of its flagship VINIA product in the United States will commence via its vinia.com website this month.
This milestone represents a turning point for BioHarvest as it brings its flagship product to the United States, the largest market in the world for nutraceutical supplements. VINIA is a product anchored in science and is the subject of multiple clinical studies published in peer-reviewed scientific journals. The launch represents an opportunity for VINIA to set a new standard for dietary supplement companies in the US$53 billion dietary supplement market (Source: Persistence Market Research).
VINIA contains Piceid Resveratrol from red grapes at levels in each capsule which is equivalent to the amount of Piceid Resveratrol in an average bottle of red wine, bringing consumers the benefits of red wine with the advantage of zero calories, zero sugar, and zero percent alcohol. VINIA daims to support heart health and improve physical energy and mental alertness, via increased blood flow and delivery of oxygen to the body’s tissues and organs.
“We are entering the US nutraceuticals market with a powerful science-based product which has the ability to contribute to the overall wellness of American consumers.” said Ilan Sobel, CEO of BioHarvest.
Information set forth in this news release includes forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Sales are dependent on market acceptance which is subject to consumer preferences that are constantly changing. There is no assurance that the Israeli market results will translate directly into US markets which may depend on different consumer preferences and more substantial marketing expenditures and resources. They can be no assurance that the launch of Vinia will lead the established resveratrol market or reach sizeable segments within the market. Projected sales of Cannabis will require the company to obtain production and/or export licensing which cannot be assured.
All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
(This information is primarily sourced from BioHarvest. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here). Image: Exterior of a High Tide store